Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Severe Aplastic Anemia with Platelet Transfusion Refractoriness
NCT06254560Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in aplastic anemia, sponsored by Institute of Hematology and Blood Diseases Hospital. Started Feb 2023; status: recruiting.
02
Drugs
rituximab
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT06254560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06254560.